Department of Radiation Oncology, Kaufman Cancer Center, University of Maryland Upper Chesapeake Health, 500 Upper Chesapeake Dr., Bel Air, MD 21014
Education and Training
Radiation Oncology Residency
Thomas Jefferson University Hospital, Philadelphia, 2017
Thomas Jefferson University Hospital, Philadelphia, 2013
Sidney Kimmel Medical College at Thomas Jefferson University, 2012
Bryn Mawr College, 2008
Dr Kamila Nowak Choi is an Assistant Professor in the Department of Radiation Oncology at the University of Maryland. Her primary practice locations include University of Maryland Upper Chesapeake Health and the Maryland Proton Treatment Center. Her primary clinical interests include the treatment of breast, GYN, thoracic and CNS malignancies, as well as use of advanced radiotherapy techniques.
Dr Nowak Choi received a bachelor's degree from Bryn Mawr College, with a major in Biology, where she conducted research on DNA methylation. She subsequently received a medical degree from Sidney Kimmel Medical College at Thomas Jefferson University in 2012.
She then completed a medical internship at Thomas Jefferson University Hospital, where she continued with her residency training. During residency, she conducted clinical research in several areas, including meningioma biology, heart sparing techniques, effects of metabolism on patient outcomes. Her research resulted in multiple peer-reviewed publications and presentations at national conferences.
Dr. Choi's focus at UM Upper Chesapeake is to give her patients access to the most advanced cancer care technologies as well as rigorous clinical trials.
In her free time, she enjoys reading, cooking, hiking, and spending time with her husband and her two children
General Radiation Oncology, External Beam Radiation, Volumetric Modulated Arc Therapy (VMAT), Intensity Modulated Radiation Therapy (IMRT), 3D Conformal Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT), Stereotactic Radiosurgery (SRS), Proton Therapy, High Dose Rate Brachytherapy, Breast cancer, Cervical cancer, Endometrial cancer, Lung cancer
- Nowak-Choi K, Palmer JD, Casey J, Chitale A, Kalchman I, Buss E, Keith SW, Hegarty SE, Curtis M, Solomides C, Shi W, Judy K, Andrews DW, Farrell C, Werner-Wasik M. Resected WHO grade I meningioma and predictors of local control. J Neurooncol 2021 Mar;152(1):145-151.
-Miller RC, Simone BA,Joseph F Lombardo JF, Taylor J, Nowak-Choi K , Ko K , Ferguson L , Donnelly A, Ali AS, Shi, W, Dicker AP, Simone NL. A Pilot Trial Using Telemedicine in Radiation Oncology: The Future of Health Care Is Virtual. Telemed Rep. 2021 Jun 14;2(1):171-178.
- Taylor JM, Song A, Nowak K, Dan T, Simone B, Harrison A, Doyle L, Lockamy V, Anne P, and Simone N. Dosimetric Comparisons of Simulation Techniques for Left-Sided Breast Cancer in the COVID-19 Era: Techniques to Reduce Viral Transmission and Respect the Therapeutic Ratio. Cureus. 2021 Feb; 13(2): e13354
- Belinsky I, Murchison AP, Evans JJ, Andrews DW, Farrell CJ, Casey JP, Curtis MT, Nowak Choi K, Werner-Wasik M, Bilyk JR. Spheno-orbital meningiomas: an analysis based on World Health organization classification and Ki-67 proliferative index. Opthalmic Plast Reconstr Surg. 34(2): 143-150 2018
- McCall NS, Simone BA, Mehta M, Zhan T, Ko K, Nowak Choi K, Rese A, Venkataraman C, Andrews DW, Anne PR, Dicker AP, Shi W, Simone NL. Onco-Metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. Breast Cancer Res Treat. 172(1):221-230. 2018
- Nowak K, Bar-Ad V, Ferguson L, McAna J, Harrison A, Yan Y, Doyle L. Using the ACR accreditation process as a quality improvement tool. J Am Coll Radiol. 2016 Feb 19
- Sun Y, Nowak K, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, Liu N, Werner-Wasik M, Wasik MA, Dicker AP, Lu B. ALK inhibitor PF02341066 (crizotinib) increased sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Molecular Cancer Therapeutics. 12(5):696-704. May 2013
- Den RB, Nowak K, Buzurovic I, Cao J, Harrison AS, Lawrence YR, Dicker AP, Showalter TN. Implanted dosimeters identify radiation overdoses during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 83(3):e371-6. July 2012